ACIU Pb Ratio vs Capex To Revenue Analysis

ACIU Stock

USD 3.38 0.09 2.74%

AC Immune financial indicator trend analysis is way more than just evaluating AC Immune prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether AC Immune is a good investment. Please check the relationship between AC Immune Pb Ratio and its Capex To Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AC Immune. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy ACIU Stock please use our How to Invest in AC Immune guide.

Pb Ratio vs Capex To Revenue

Pb Ratio vs Capex To Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of AC Immune Pb Ratio account and Capex To Revenue. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between AC Immune's Pb Ratio and Capex To Revenue is -0.42. Overlapping area represents the amount of variation of Pb Ratio that can explain the historical movement of Capex To Revenue in the same time period over historical financial statements of AC Immune, assuming nothing else is changed. The correlation between historical values of AC Immune's Pb Ratio and Capex To Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Pb Ratio of AC Immune are associated (or correlated) with its Capex To Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Revenue has no effect on the direction of Pb Ratio i.e., AC Immune's Pb Ratio and Capex To Revenue go up and down completely randomly.

Correlation Coefficient

-0.42

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Pb Ratio

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Most indicators from AC Immune's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into AC Immune current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AC Immune. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy ACIU Stock please use our How to Invest in AC Immune guide.At this time, AC Immune's Tax Provision is comparatively stable compared to the past year. Enterprise Value is likely to gain to about 498.1 M in 2024, whereas Selling General Administrative is likely to drop slightly above 8.3 M in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	79.0M	74.8M	13.8M	13.1M
Cost Of Revenue	62.3M	60.3M	54.6M	45.8M

Total Operating Expenses Cost Of Revenue

AC Immune fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Net Receivables	Other Current Assets	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse
Total Assets		0.91	0.9	1.0	0.94	0.98	-0.47	0.06	0.81	0.83	-0.04	0.75	0.95	0.98	0.82	0.81	0.87	0.54	-0.8	0.5	0.52	0.97	0.88	0.69	0.93	0.91
Other Current Liab	0.91		0.96	0.9	0.86	0.83	-0.6	-0.03	0.59	0.89	-0.06	0.74	0.98	0.83	0.86	0.87	0.92	0.36	-0.58	0.65	0.34	0.82	0.89	0.77	0.94	0.91
Total Current Liabilities	0.9	0.96		0.89	0.83	0.84	-0.51	-0.04	0.62	0.82	-0.17	0.68	0.98	0.84	0.78	0.83	0.87	0.51	-0.6	0.57	0.49	0.84	0.82	0.69	0.92	0.84
Total Stockholder Equity	1.0	0.9	0.89		0.94	0.98	-0.46	0.07	0.82	0.83	-0.04	0.74	0.94	0.98	0.81	0.81	0.86	0.54	-0.81	0.49	0.53	0.97	0.88	0.68	0.92	0.9
Other Liab	0.94	0.86	0.83	0.94		0.96	-0.3	0.08	0.85	0.7	0.02	0.63	0.89	0.96	0.66	0.7	0.75	0.49	-0.84	0.31	0.47	0.96	0.75	0.52	0.9	0.8
Net Tangible Assets	0.98	0.83	0.84	0.98	0.96		-0.35	0.09	0.9	0.75	-0.04	0.69	0.9	1.0	0.72	0.72	0.78	0.59	-0.89	0.34	0.58	0.99	0.81	0.57	0.9	0.85
Retained Earnings	-0.47	-0.6	-0.51	-0.46	-0.3	-0.35		0.1	-0.06	-0.76	-0.34	-0.86	-0.55	-0.31	-0.84	-0.86	-0.75	0.12	0.01	-0.95	0.07	-0.3	-0.75	-0.89	-0.59	-0.66
Accounts Payable	0.06	-0.03	-0.04	0.07	0.08	0.09	0.1		0.24	-0.1	0.0	-0.16	-0.02	0.08	0.03	-0.13	-0.12	-0.41	-0.26	-0.08	-0.47	0.09	0.04	-0.26	-0.05	-0.05
Cash	0.81	0.59	0.62	0.82	0.85	0.9	-0.06	0.24		0.45	-0.12	0.48	0.68	0.9	0.44	0.43	0.46	0.51	-0.99	0.01	0.5	0.91	0.57	0.22	0.68	0.63
Other Assets	0.83	0.89	0.82	0.83	0.7	0.75	-0.76	-0.1	0.45		0.09	0.83	0.87	0.72	0.95	0.91	0.96	0.28	-0.44	0.72	0.29	0.7	0.97	0.93	0.89	0.96
Net Receivables	-0.04	-0.06	-0.17	-0.04	0.02	-0.04	-0.34	0.0	-0.12	0.09		0.29	-0.05	-0.07	0.15	0.18	0.04	-0.17	0.14	0.27	-0.1	-0.12	0.09	0.17	0.05	0.03
Other Current Assets	0.75	0.74	0.68	0.74	0.63	0.69	-0.86	-0.16	0.48	0.83	0.29		0.76	0.66	0.88	0.94	0.84	0.23	-0.44	0.78	0.28	0.65	0.88	0.88	0.82	0.83
Total Liab	0.95	0.98	0.98	0.94	0.89	0.9	-0.55	-0.02	0.68	0.87	-0.05	0.76		0.89	0.85	0.87	0.92	0.49	-0.67	0.58	0.48	0.89	0.89	0.75	0.98	0.9
Total Current Assets	0.98	0.83	0.84	0.98	0.96	1.0	-0.31	0.08	0.9	0.72	-0.07	0.66	0.89		0.68	0.7	0.76	0.6	-0.9	0.31	0.59	1.0	0.78	0.54	0.88	0.83
Common Stock	0.82	0.86	0.78	0.81	0.66	0.72	-0.84	0.03	0.44	0.95	0.15	0.88	0.85	0.68		0.93	0.95	0.19	-0.43	0.82	0.2	0.66	0.98	0.93	0.86	0.93
Property Plant Equipment	0.81	0.87	0.83	0.81	0.7	0.72	-0.86	-0.13	0.43	0.91	0.18	0.94	0.87	0.7	0.93		0.95	0.26	-0.39	0.85	0.29	0.69	0.92	0.94	0.9	0.86
Property Plant And Equipment Net	0.87	0.92	0.87	0.86	0.75	0.78	-0.75	-0.12	0.46	0.96	0.04	0.84	0.92	0.76	0.95	0.95		0.35	-0.44	0.76	0.34	0.74	0.95	0.93	0.93	0.93
Current Deferred Revenue	0.54	0.36	0.51	0.54	0.49	0.59	0.12	-0.41	0.51	0.28	-0.17	0.23	0.49	0.6	0.19	0.26	0.35		-0.51	-0.06	0.99	0.59	0.27	0.21	0.45	0.35
Net Debt	-0.8	-0.58	-0.6	-0.81	-0.84	-0.89	0.01	-0.26	-0.99	-0.44	0.14	-0.44	-0.67	-0.9	-0.43	-0.39	-0.44	-0.51		0.03	-0.5	-0.9	-0.56	-0.2	-0.67	-0.63
Non Current Assets Total	0.5	0.65	0.57	0.49	0.31	0.34	-0.95	-0.08	0.01	0.72	0.27	0.78	0.58	0.31	0.82	0.85	0.76	-0.06	0.03		-0.04	0.31	0.71	0.86	0.58	0.61
Non Currrent Assets Other	0.52	0.34	0.49	0.53	0.47	0.58	0.07	-0.47	0.5	0.29	-0.1	0.28	0.48	0.59	0.2	0.29	0.34	0.99	-0.5	-0.04		0.58	0.28	0.25	0.46	0.35
Cash And Short Term Investments	0.97	0.82	0.84	0.97	0.96	0.99	-0.3	0.09	0.91	0.7	-0.12	0.65	0.89	1.0	0.66	0.69	0.74	0.59	-0.9	0.31	0.58		0.76	0.52	0.86	0.81
Common Stock Total Equity	0.88	0.89	0.82	0.88	0.75	0.81	-0.75	0.04	0.57	0.97	0.09	0.88	0.89	0.78	0.98	0.92	0.95	0.27	-0.56	0.71	0.28	0.76		0.89	0.92	0.97
Common Stock Shares Outstanding	0.69	0.77	0.69	0.68	0.52	0.57	-0.89	-0.26	0.22	0.93	0.17	0.88	0.75	0.54	0.93	0.94	0.93	0.21	-0.2	0.86	0.25	0.52	0.89		0.79	0.84
Non Current Liabilities Total	0.93	0.94	0.92	0.92	0.9	0.9	-0.59	-0.05	0.68	0.89	0.05	0.82	0.98	0.88	0.86	0.9	0.93	0.45	-0.67	0.58	0.46	0.86	0.92	0.79		0.91
Capital Surpluse	0.91	0.91	0.84	0.9	0.8	0.85	-0.66	-0.05	0.63	0.96	0.03	0.83	0.9	0.83	0.93	0.86	0.93	0.35	-0.63	0.61	0.35	0.81	0.97	0.84	0.91

Click cells to compare fundamentals

AC Immune Account Relationship Matchups

AC Immune fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	299.3M	238.7M	261.4M	185.9M	182.8M	177.6M
Other Current Liab	11.8M	11.1M	16.7M	9.4M	11.1M	9.5M
Total Current Liabilities	17.5M	14.0M	20.0M	11.5M	13.6M	12.8M
Total Stockholder Equity	272.4M	215.5M	232.0M	169.0M	160.6M	158.5M
Other Liab	7.5M	7.5M	7.1M	3.2M	3.7M	5.0M
Net Tangible Assets	272.4M	215.5M	181.6M	118.6M	136.4M	145.5M
Retained Earnings	(75.5M)	(132.9M)	(200.9M)	(264.0M)	(316.2M)	(300.4M)
Accounts Payable	142K	2.2M	2.0M	929K	1.7M	1.4M
Cash	193.6M	160.9M	82.2M	31.6M	78.5M	107.1M
Net Receivables	1.4M	1.6M	975K	800K	15.0M	15.8M
Other Current Assets	4.2M	4.0M	3.0M	4.7M	6.4M	6.8M
Total Liab	26.8M	23.3M	29.5M	16.9M	22.2M	19.1M
Total Current Assets	292.8M	231.8M	202.6M	128.1M	125.2M	157.9M
Common Stock	1.4M	1.5M	1.8M	1.8M	2.1M	1.5M
Property Plant Equipment	6.2M	6.6M	8.0M	7.1M	8.1M	8.5M
Property Plant And Equipment Net	6.2M	6.6M	8.0M	7.1M	6.9M	4.7M
Current Deferred Revenue	4.5M	306K	717K	587K	138K	131.1K
Net Debt	(190.7M)	(158.7M)	(79.3M)	(28.8M)	(75.0M)	(78.7M)
Non Current Assets Total	6.5M	7.0M	58.8M	57.8M	57.7M	60.5M
Non Currrent Assets Other	6.5M	334K	363K	361K	415.2K	394.4K
Cash And Short Term Investments	288.6M	225.9M	198.2M	122.6M	103.0M	162.9M
Common Stock Total Equity	1.1M	1.4M	1.4M	1.5M	1.8M	1.3M
Common Stock Shares Outstanding	71.1M	71.9M	75.0M	83.6M	84.7M	73.3M
Short Term Investments	95M	65M	116M	91M	24.6M	46.4M
Liabilities And Stockholders Equity	299.3M	238.7M	261.4M	185.9M	182.8M	193.9M
Non Current Liabilities Total	9.3M	9.2M	9.4M	5.5M	8.6M	6.9M
Capital Lease Obligations	2.3M	2.2M	2.9M	2.8M	3.5M	3.7M
Inventory	(1.4M)	(1.9M)	(1.4M)	1.0	(622K)	(590.9K)
Other Stockholder Equity	346.5M	346.8M	431.1M	431.2M	474.8M	300.1M
Property Plant And Equipment Gross	6.2M	6.6M	15.6M	7.1M	17.9M	18.8M
Accumulated Other Comprehensive Income	179.4M	(3.5M)	0.0	10K	(51K)	(48.5K)
Short Term Debt	1.1M	443K	570K	548K	672K	402.5K
Short Long Term Debt Total	2.9M	2.2M	2.9M	2.8M	3.5M	2.1M
Net Invested Capital	273.1M	215.5M	232.0M	169.0M	160.6M	211.4M
Net Working Capital	275.3M	217.7M	182.6M	116.6M	111.6M	137.5M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for ACIU Stock Analysis

When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC